ClinicalTrials.gg
RecruitingNCT05853965BELI(E)VEUpdated May 18, 2026

Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma

A Phase 1/2 interventional study of Belantamab mafodotin, Venetoclax in Multiple Myeloma and Multiple Myeloma in Relapse, sponsored by Universitätsklinikum Hamburg-Eppendorf. Recruiting at 5 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by Universitätsklinikum Hamburg-Eppendorf · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies testing belantamab mafodotin in Multiple Myeloma — 15 open to participants now, 35 under way, 8 of them phase 3. belantamab mafodotin · Multiple Myeloma.

Planned enrollment
26th of 49
45 · median 50
Started
2023
with 3 others
Phase 1/2
17 of 49
3 open now
Primary completion
2027-04
later than 17 of 34 live
Registered
30th of 49
by date

Among the 49 studies testing belantamab mafodotin in Multiple Myeloma, this one is the 26th largest by planned enrollment, is one of 4 that started in 2023, is one of 17 in phase 1/2, reaches primary completion later than 17 of the 34 other live ones, and was the 30th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 49 studies testing belantamab mafodotin in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About belantamab mafodotin

belantamab mafodotin: first FDA approval 2020 (Blenrep), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies testing belantamab mafodotin in Multiple Myeloma, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn about the safety and efficacy of the drug combination belantamab mafodotin and venetoclax, with or without the addition of dexamethasone, in patients with relapsed/refractory multiple myeloma bearing the translocation t(11;14)

03

Conditions studied

  • Multiple Myeloma
  • Multiple Myeloma in Relapse

Browse trials for

Keywords

  • t(11;14)
  • venetoclax
  • belantamab mafodotin
  • multiple myeloma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

t(11;14) Multiple Myeloma (RRMM)

Inclusion criteria

Inclusion criteria:

  1. Subjects must be ≥ 18 years of age.
  2. Subjects must have an (ECOG) performance status of ≤ 2
  3. Subjects must voluntarily sign and date an in-formed consent form
  4. Subjects must have had documented multiple myeloma requiring treatment as defined by the criteria below:

    Monoclonal plasma cells in the bone marrow > 10% and/or presence of a proven plasmacytoma at some point in their disease history requiring treatment according diag-nostic criteria (IMWG updated criteria 2014, Rajkumar et al. 2014) with measurable dis-ease at screening (serum M-protein > 500 mg/dL or urine M protein 200 mg/24h, in case of oligosecretory MM serum free light chain > 10mg/dL and abnormal kap-pa/lambda free light chain ratio)

  5. Cytogenetics/FISH confirming t(11;14)
  6. Prior treatment requirements:

    Prior treatment requirements:

    a. Subjects must have received at least 1 prior treatment line (induction, high-dose, consolidation and maintenance is considered as one treatment line). All patients have to have received at least one proteasome inhibitor and at least one immunomodulatory agent and at least one anti-CD38 monoclonal antibody.

    b. Subjects must have documented evidence of progressive disease on or after the last treatment line.

    c. Subjects with a history of SCT are eligible for study participation provided the following eligibility criteria are met: i. ASCT was >100 days prior to initiating study treatment, and ii. No active bacterial, viral, or fungal in-fection(s) present.

  7. Subjects must have adequate organ function, defined as follows:

    a. ≥8.0 g/dL (without transfusion of red blood cells for the past 14 days) b. ≥ 1.5 x109/L (with-out growth factor support for the past 14 days) c. count more or equal 75 x109/L (with-out growth factor or platelet stimulating agents for the past 14 days) d. Adequate hepatic function per local laborato-ry reference range as follows: i. (AST) ≤ 2,5 x (ULN); ii. Alanine aminotransferase (ALT) ≤ 2.5 x ULN iii. Total ≤ 1.5 x ULN, except in subjects with congenital bilirubinemia, such as Gilbert syndrome (direct bili-rubin ≤ 1.5 x ULN). Isolated bilirubin ≥1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%.

    e. Subjects must have adequate renal function as demonstrated by ≥30 mL/min/ 1.73 m2 as calculated by Modified Diet in Renal Disease (MDRD) formula f. Spot urine (albumin/creatinine ratios (spot urine) \<500 mg/g (56 mg/mmol) OR Urine Dipstick Negative/trace (if 1+ only eligible if confirmed \<500 mg/g (56 mg/mmol) by albumin/creatinine ratio (spot urine from first void) g. Corrected serum calcium ≤ 14 mg/dL (≤3,5 mmol/L); or free ionized calcium ˂ 6,5 mg/dL (˂1,6 mmol/L)

  8. A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:

    1. Is not a woman of (WOCBP) OR
    2. Is a WOCBP and using a method that is highly effective
  9. Male participants are eligible to participate if they agree to the refrain from donating sperm and either bei abstinent from heterosexual intercourse or agree to use a highly effective contraceptive method during the intervention period and for 6 months after the last dose of study treatment to allow for clearance of any altered sperm
  10. All subjects must agree to refrain from donating blood while on study drug and for 28 days after discontinuation from this study treatment.
  11. All subjects must agree not to share study medication.
  12. All prior treatment-related toxicities (defined by National Cancer Institute- Common Toxicity Criteria for Adverse Events (), version 5.0) must be ≤ Grade 1 at the time of en-rolment except for alopecia.

Exclusion criteria

Exclusion Criteria:

  1. Subject has received prior Venetoclax and/or anti BCMA treatment.
  2. Participant has used an drug or approved systemic anti-myeloma therapy with-in 14 days or five half-lives, whichever is short-er, preceding the first dose of study drug. The only exception is emergency use of a short course of (equivalent of Dexa-methasone 40 mg/day for a maximum of 4 days) up to 7 days before treatment.
  3. Participant has had plasmapheresis or radia-tion therapy within 7 days prior to first dose of study treatment
  4. Participant has current corneal epithelial dis-ease except mild changes in corneal epitheli-um
  5. Participant has current unstable liver or biliary disease
  6. Participant has a presence of active renal con-dition (infection, requirement for dialysis or any other condition that could affect participant's safety).
  7. Participant has had major surgery ≤ 4 weeks prior to initiating study treatment. Kyphoplasty is not considered a major surgery.
  8. Participant must not use contact lenses while participating in this study. Bandage contacts may be prescribed by an eye care professional if needed.
  9. Participant has any evidence of active mucosal or internal bleeding or other gastrointestinal disease that may significantly alter the absorp-tion of oral drugs.
  10. Participant has evidence of cardiovascular risk as defined in the protocol
  11. Participant has known immediate or delayed reaction or idiosyncratic reac-tions to IMPs or drugs chemically related to IMPs, or any of the components of the study treatment
  12. Participant has an invasive other than disease under study within 5 years before trial inclusion, except

    • Adequately treated in situ carcinoma of the cervix uteri or the breast;
    • Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;
    • Prostate cancer Gleason grade 6 or lower AND with stable Prostate Specific Antigen (PSA) levels off treatment;
    • Previous malignancy with no current evi-dence of disease, and which was confined and surgically resected (or treated with other mo-dalities) with curative intent and unlikely to im-pact survival during the duration of the study.
  13. Participant is pregnant or lactating
  14. Participants who have had prior stem cell transplant.
  15. Participants with symptomatic amyloidosis, ac-tive POEMS syndrome (polyneuropathy, or-ganomegaly, endocrinopathy, monoclonal plasmaproliferative disorder, skin changes) or active plasma cell leukaemia at the time of screening.
  16. Participants with any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions (including lab abnormalities) that could interfere with participant's safety, ob-taining or compliance to the study procedures.
  17. Subject is known to be seropositive for (HIV) or (defined by a positive test for hepatitis B sur-face antigen (HBsAg) or antibodies to hepatitis B surface and core antigen (anti HBs and anti HBc respectively), or (anti-HCV an-tibody positive or HCV RNA quantitation posi-tive).
  18. Current immune or inflammatory conditions re-quiring treatment (e.g. systemic lupus erythematosus, rheumatoid ar-thritis).
  19. Subject must not have received any live vac-cines within 8 weeks prior to first dose of study treatment.
  20. Subject must not use or anticipate the use of prohibited medications or foods during study participation.
  21. Subject does not have a history of or show any signs of known meningeal/central nervous sys-tem involvement by myeloma.
  22. Evidence of other uncon-trolled condition(s) that is likely to interfere with the study proce-dures or results, or that in the opinion of the investigator, would constitute a hazard for the participation in this study.
  23. Subject is known or suspected of not being able to comply with the study protocol. Subject has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (e.g., compromise the well-being) or that could prevent, limit or confound the pro-tocol-specified assessments.
  24. Treatment with any of the following within 7 days prior to the first dose of study drug:

    1. moderate or strong cytochrome P450 3A () inhibitors
    2. moderate or strong CYP3A inducers
  25. Administration or consumption of any of the fol-lowing within 3 days prior to the first dose of study drug:

    1. grapefruit or grapefruit products
    2. Seville oranges (including marmalade con-taining Seville oranges)
    3. star fruit
  26. Participation in any other clinical trial (with the exclusion of observational studies)
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Belantamab Mafodotin 1.9 mg/kg Q6W Venetoclax 400mg QD

    Drug: Belantamab mafodotin, Venetoclax

  • Experimental
    Cohort 2

    Belantamab Mafodotin 1.9 mg/kg Q6W Venetoclax 800mg QD

    Drug: Belantamab mafodotin, Venetoclax

  • Experimental
    Cohort 3

    Belantamab Mafodotin 1.9 mg/kg Q6W Venetoclax 400mg QD Dexamethasone 40mg Q1W (20mg for subjects ≥ 75 years)

    Drug: Belantamab mafodotin, Venetoclax

  • Experimental
    Cohort 4

    Belantamab Mafodotin 1.9 mg/kg Q6W Venetoclax 800mg QD Dexamethasone 40mg Q1W (20mg for subjects ≥ 75 years)

    Drug: Belantamab mafodotin, Venetoclax

Interventions

06

What researchers measure

Primary outcomes

  1. Recommended Phase II dose (RP2D)

    Establishment of Recommended Phase II dose (RP2D), Evaluation of safety profile, including maximum tolerated dose

    Time frame: approx. 9 months

Secondary outcomes

  1. Overall Response Rate

    Overall Response Rate

    Time frame: through study completion, an average of 2 years

  2. Minimal residual disease (MRD) negativity

    Minimal residual disease (MRD) negativity rate and duration

    Time frame: through study completion, an average of 2 years

  3. Progression free survival (PFS)

    Progression free survival (PFS)

    Time frame: through study completion, an average of 2 years

  4. Duration of response (DOR)

    Duration of response (DOR)

    Time frame: through study completion, an average of 2 years

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Apr 2027, 46 months after the start.

Of 103 non-industry phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 94. This study's planned 46 months is below that.

Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2023
First posted
May 11, 2023
StartActual
Jun 28, 2023
Primary completionEst.
Apr 2027
CompletionEst.
Dec 2028
Last update
May 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05853965
Responsible party
Sponsor
First posted
May 11, 2023
Start date
Jun 28, 2023
Primary completion
Apr 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
May 18, 2026

Study contacts

Katja Weisel
Contact
k.weisel@uke.de
+4940741051410
Lisa Leypoldt
Contact
l.leypoldt@uke.de
Katja Weisel
principal investigator · Universitätsklinikum Hamburg-Eppendorf

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Belantamab mafodotin · Venetoclax

Start the discussion